ZA200002693B - Transdermal estrogen agonist-antagonist therapy. - Google Patents

Transdermal estrogen agonist-antagonist therapy.

Info

Publication number
ZA200002693B
ZA200002693B ZA200002693A ZA200002693A ZA200002693B ZA 200002693 B ZA200002693 B ZA 200002693B ZA 200002693 A ZA200002693 A ZA 200002693A ZA 200002693 A ZA200002693 A ZA 200002693A ZA 200002693 B ZA200002693 B ZA 200002693B
Authority
ZA
South Africa
Prior art keywords
estrogen agonist
antagonist therapy
transdermal estrogen
transdermal
estrogen
Prior art date
Application number
ZA200002693A
Other languages
English (en)
Inventor
Paul Andrew Da Silva-Jardine
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200002693B publication Critical patent/ZA200002693B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
ZA200002693A 1999-06-01 2000-05-30 Transdermal estrogen agonist-antagonist therapy. ZA200002693B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13716499P 1999-06-01 1999-06-01

Publications (1)

Publication Number Publication Date
ZA200002693B true ZA200002693B (en) 2001-11-30

Family

ID=22476088

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200002693A ZA200002693B (en) 1999-06-01 2000-05-30 Transdermal estrogen agonist-antagonist therapy.

Country Status (16)

Country Link
EP (1) EP1057480B1 (es)
JP (1) JP2001002588A (es)
KR (1) KR20010029770A (es)
AT (1) ATE269698T1 (es)
AU (1) AU3781000A (es)
CA (1) CA2310272A1 (es)
CO (1) CO5170459A1 (es)
DE (1) DE60011710T2 (es)
DK (1) DK1057480T3 (es)
ES (1) ES2220346T3 (es)
HU (1) HUP0002085A3 (es)
IL (1) IL136376A0 (es)
NZ (1) NZ504868A (es)
PE (1) PE20010207A1 (es)
PT (1) PT1057480E (es)
ZA (1) ZA200002693B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
IL147640A0 (en) * 2000-06-01 2002-08-14 Watson Pharmaceuticals Inc Transdermal delivery of lasofoxifene
US9510946B2 (en) 2012-09-06 2016-12-06 Edwards Lifesciences Corporation Heart valve sealing devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis

Also Published As

Publication number Publication date
HUP0002085A3 (en) 2002-09-30
ATE269698T1 (de) 2004-07-15
DE60011710T2 (de) 2005-06-30
DK1057480T3 (da) 2004-11-08
IL136376A0 (en) 2001-06-14
CA2310272A1 (en) 2000-12-01
CO5170459A1 (es) 2002-06-27
HUP0002085A2 (en) 2001-03-28
EP1057480A2 (en) 2000-12-06
AU3781000A (en) 2000-12-07
PT1057480E (pt) 2004-10-29
EP1057480A3 (en) 2002-01-09
NZ504868A (en) 2001-09-28
EP1057480B1 (en) 2004-06-23
HU0002085D0 (en) 2000-08-28
PE20010207A1 (es) 2001-02-28
KR20010029770A (ko) 2001-04-16
JP2001002588A (ja) 2001-01-09
ES2220346T3 (es) 2004-12-16
DE60011710D1 (de) 2004-07-29

Similar Documents

Publication Publication Date Title
GR3035774T3 (en) Substituted benzolactam compounds as substance p antagonists
EP1039887A4 (en) PROCESS FOR THE TREATMENT OF NEURO AND NEPHROTOXICITIES AND THERAPEUTIC TOXICITIES WITH AMINOTHIOL COMPOUNDS
GB2364725B (en) Method for treatment of underground reservoirs
GB9915354D0 (en) Method for treatment of underground reservoirs
EP1014982A4 (en) TROGLITAZONE COMPOUNDS FOR TREATING THE CLIMATE
HUP0105036A3 (en) Imidazo-quinolin derivatives for treating sexual disturbances
AU2002210462A1 (en) Transdermal therapeutic system for treating restless-legs-syndrome
IL144996A0 (en) Method for treating exercise induced asthma
HK1040184A1 (zh) 治療青光眼之組合療法
PL344331A1 (en) Combination therapy for treatment of refractory depression
FI991220A (fi) Menetelmä massan käsittelemiseksi
HU0002509D0 (en) Combination therapy for treatment of migraine
GB9930697D0 (en) Method of treating a textile
ZA200002693B (en) Transdermal estrogen agonist-antagonist therapy.
ZA9810215B (en) 2-Aryl-3-Aroylbenzo[b]thiophenes useful for the treatment of estrogen deprivation syndrome.
HK1043935A1 (zh) 治療copd的方法
HK1048441A1 (en) Drug for treating fractures
EP1199347A4 (en) METHOD FOR TREATING RAW OIL
IL126657A0 (en) Method for treating or preventing ischemia-reperfusion injury
GB2332849B (en) Apparatus for the treatment of soil
AU3988099A (en) Combination therapy for treating hypercholesterolemia
GB0009808D0 (en) Roller support for grass treatment machine
HUP0105152A3 (en) Method for treatment of headache
AU3990399A (en) Combination therapy for treating hypercholesterolemia
TW433158U (en) Improved structure for special surface treatment machine of granite